The introduction of recent bills allowing for companies to sell novel and untested cannabinoids, leaves consumers open to possible adverse effects and possible complications from inhalation or consumption of these cannabinoids, with the mass production of the cannabinoids , introduction of byproducts and unclean product can lead to harm. The identification of the cannabinoids and their binding pockets, with in-silico data contributes to pre-investigational biologic studies and toxicology studies of consumed cannabinoids, while providing pertinent information for medicinal and organic chemists for possible drug design of novel analogs to surpass parent scaffolds.